Drug Profile
ImmTher
Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator DOR BioPharma
- Class Antineoplastics; Phosphatidylcholines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bone cancer; Colorectal cancer; Malignant melanoma; Prostate cancer
Most Recent Events
- 17 Sep 1998 Endorex received a Japanese patent for ImmTher
- 30 Jun 1998 ImmTher has Orphan Drug status for the treatment of Ewing's sarcoma in the US
- 18 Mar 1998 Phase-II clinical trials for Bone cancer in USA (Unknown route)